FDA approved Latindra for type 1 diabetes treatment
Lantidra is the first FDA approved allogeneic pancreatic islet cellular therapy
It is believed to work through the secretion of insulin from the infused allogeneic islet beta cells
A clinical trial demonstrated positive outcomes with a significant number of participants not requiring insulin for over a year
Side effects such as sickness, tiredness, and gastrointestinal discomfort were observed
Safety and efficacy of Lantidra have not been established in patients with liver disease or renal failure, or in those who have received a renal transplant
Step into a world of hope for individuals with type 1 diabetes, as Lantidra opens doors to a future where the need for insulin may be greatly diminished